Bolt Biotherapeutics logo
BOLTBolt Biotherapeutics
Trade BOLT now
Bolt Biotherapeutics primary media

About Bolt Biotherapeutics

Bolt Biotherapeutics (NASDAQ:BOLT) is a biotechnology company dedicated to revolutionizing cancer treatment through the development of its innovative immuno-oncology platforms. The company's flagship projects focus on harnessing the body's immune system to target and destroy cancer cells, leveraging its cutting-edge research in the field of Immune-Stimulating Antibody Conjugates (ISACs). Bolt Biotherapeutics aims to pioneer treatments that offer improved outcomes for patients with various types of cancer. With a commitment to innovation and patient care, Bolt Biotherapeutics is actively advancing its pipeline of potential cancer therapies, driven by a deep understanding of the complex interactions within the tumor microenvironment.

What is BOLT known for?

Snapshot

Public US
Ownership
2015
Year founded
100
Employees
Redwood City, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
Redwood City, US

Products and/or services of Bolt Biotherapeutics

  • A pioneering project focusing on immuno-oncology, aiming to harness the body's immune system to fight cancer more effectively.
  • Development of a next-generation bolt-on technology designed to enhance the efficacy of existing cancer therapies.
  • Creation of a unique platform for targeted drug delivery, especially for hard-to-reach tumors, improving treatment accuracy and reducing side effects.
  • Advancement in personalized cancer vaccine technology, tailoring treatments to individual patient's tumor markers for increased effectiveness.
  • Exploration of antibody-drug conjugates (ADC) utilizing cutting-edge linker technology for improved stability and tumor targeting.
  • Research into modulating the tumor microenvironment to support immune system access and activity against cancer cells.

Bolt Biotherapeutics executive team

  • Mr. William P. QuinnCEO, CFO, President, Secretary & Director
  • Mr. Grant Yonehiro C.F.A., M.B.A.COO & Chief Business Officer
  • Ms. Sarah NemecSenior VP of Finance & Principal Accounting Officer
  • Dr. Michael N. Alonso Ph.D.Senior Vice President of Research
  • Mr. Justin KenkelSenior Principal Scientist

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.